et al. Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. eTable 1. Demographics and baseline biomarkers and cognitive test scores by last clinical follow-up diagnosis eTable 2. Cross-sectional analyses, including sensitivity analyses eTable 3. Longitudinal analyses based on linear mixed effects models, including sensitivity analyses eTable 4. Cross-sectional analyses, including dose model for APOE ε4 eFigure 1. Baseline test score versus age for 315 cognitively normal subjects eFigure 2. Longitudinal scores on neuropsychological tests for 158 subjects who were cognitively normal at baseline and had at least one follow-up test visit eFigure 3. Longitudinal Immediate Recall and Delayed Recall scores for 158 subjects who were cognitively normal at baseline and had at least one follow-up test visit
Converted to other dementias or CIs (N = 6) Age at baseline (yrs) 47.1 (48) ± 18.3 65.6 (67) ± 11.2 75.9 (75) ± 6.9 77.1 (76) ± 5.9 [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] 72.8 (76.5) ± 11.2 [52-82] Male 76 (50%) 53 (39%) 10 (71%) 2 (29%) 4 (66.7%) Caucasian 123 (84%) 128 (95%) 12 (86%) 7 (100%) 6 (100%) APOE ε4 allele(s) 58 (38%) 39 (29%) 6 (43%) 4 (57%) 1 (17%) Education (yrs) 16.3 (16) ± 2.6 [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] 16.0 (16) ± 2.7 [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] 15.9 (16) ± 2.5 [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] 15.9 (16) ± 2.5 [12] [13] [14] [15] [16] [17] [18] 16.8 (16.5) ± 1.0 [16] [17] [18] 29.2 (30) ± 1.0 [26] [27] [28] [29] [30] 29.3 (30) ± 0.9 [25] [26] [27] [28] [29] [30] 29.1 (29.5) ± 1.1 [27] [28] [29] [30] 28.7 (29) ± 1.8 [25] [26] [27] [28] [29] [30] 29.2 (29. 50.4 (51.0) ± 8.0 [40.8-64.4] 35.3 (39.5) ± 11.9 [11.7-42.9] CSF F 2 -IsoPs (pg/ml) 28.9 (28) ± 8.7 30.4 (30) ± 9.6 34.7 (35) ± 8.7 30.3 (30) ± 8.9 Model 1 0.24 0.004 (4e-04); <0.001 -0.03 (0.02); 0.10 -0.005 (0.003); 0.07 -0.004 (0.02); 0.78 Age≥60 0.10 0.005 (0.001); <0.001 -0.04 (0.02); 0.06 -0.005 (0.004); 0.24 -0.006 (0.02); 0.81 Model 2 0.25 0.004 (4e-04); <0.001 -0.03 (0.02); 0.07 -0.004 (0.003); 0.18 -0.008 (0.02); 0.64 -6e-05 ( 6e-05); 0.32 2e-04 (6e-04); 0.76 0.002 (9e-04); 0.04 Age≥60 0.10 0.005 (0.002); 0.005 -0.04 (0.02); 0.052 -0.004 (0.004); 0.36 -0.02 (0.02); 0.47 -1e-04 (8e-05); 0.12 3e-04 (8e-04); 0.70 0.002 (0.001); 0.18 Model 3 0.26 0.004 (4e-04); <0.001 -0.03 (0.02); 0.05 -0.005 (0.003); 0.13 -0.008 (0.02); 0.63 -0.06 (0.02); 0.007 3e-04 (5e-04); 0.62 0.002 (9e-04); 0.03 Age≥60 0.10 0.005 (0.002); 0.003 -0.04 (0.02); 0.05 -0.005 (0.004); 0.29 -0.01 (0.02); 0.57 -0.04 (0.03); 0.15 1e-04 (7e-04); 0.89 0.002 (0.001); 0.23 Model 4 0.23 0.004 (5e-4); <0.001 -0.03 (0.02); 0.08 -0.003 (0.003); 0.31 -0.001 (0.02); 0.94 -4e-05 ( 6e-05); 0.56 3e-04 (6e-04); 0.66 0.002 (9e-04); 0.04 Age≥60 0.08 0.004 (0.002); 0.03 -0.05 (0.02); 0.05 -0.001 (0.005); 0.76 -0.01 (0.027); 0.69 -1e-04 (9e-05); 0.28 4e-04 (9e-04); 0.62 0.002 (0.001); 0.15
Log 10 (Trail B)
Model 1 0.30 0.005 (5e-04); <0.001 -0.03 (0.02); 0.07 -0.02 (0.003); <0.001 0.03 (0.02); 0.12 Age≥60 0.17 0.006 [0.002) ; <0.001 -0.05 (0.02); 0.06 -0.02 (0.004); <0.001 0.03 (0.02); 0.24 Model 2 0.31 0.004 (5e-04); <0.001 -0.03 (0.02); 0.05 -0.01 (0.003); <0.001 0.02 (0.02); 0.24 -1e-04 (6e-05); 0.05 5e-04 (6e-04); 0.41 0.003 (0.001); 0.007 Age≥60 0.18 0.005 (0.002); 0.003 -0.04 (0.02); 0.06 -0.02 (0.005); <0.001 0.01 (0.03); 0.65 -2e-04 (8e-05); 0.06 0.001 (8e-04); 0.15 0.001 (0.001); 0.31 Model 3 0.30 0.004 (5e-04); <0.001 -0.04 (0.02); 0.04 -0.01 (0.003); <0.001 0.02 (0.02); 0.16 -0.03 (0.02); 0.27 1e-04 (6e-04); 0.83 0.002 (0.001); 0.01 Age≥60 0.16 0.005 (0.002); 0.002 -0.05 (0.02); 0.06 -0.02 (0.005); <0.001 0.02 (0.03); 0.40 -0.02 (0.03); 0.47 8e-04 (8e-04); 0.33 0.001 (0.001); 0.45 © 2014 American Medical Association. All rights reserved. 4 Model 4 0.28 0.004 (5e-04); <0.001 -0.03 (0.02); 0.08 -0.01 (0.004); <0.001 0.02 (0.02); 0.29 -1e-04 (7e-05); 0.09 6e-04 (7e-04); 0.34 0.003 (0.001); 0.01 Age≥60 0.14 0.005 (0.002); 0.02 -0.04 (0.03); 0.14 -0.01 (0.005); 0.006 0.00 (0.03); 0.99 -2e-04 (1e-04); 0.08 0.001 (0.001); 0.12 0.001 (0.001); 0.48
Cognitive Test

Ad
Category Fluency
Model 1 0.16 -0.09 (0.02); <0.001 0.2 (0.6); 0.76 0.6 (0.1); <0.001 0.4 (0.6); 0.53 Age≥60 0.17 -0.13 (0.05); 0.014 1.4 (0.8); 0.08 0.8 (0.1); <0.001 0.1 (0.8); 0.89 Model 2 0.16 -0.08 (0.02); <0.001 0.1 (0.6); 0.85 0.6 (0.1); <0.001 0.6 (0.6); 0.35 0.004 (0.002); 0.07 -0.04 (0.02); 0.10 -0.02 (0.04); 0.63 Age≥60 0.18 -0.09 (0.06); 0.09 1.3 (0.8); 0.11 0.8 (0.2); <0.001 0.6 (0.9); 0.46 0.005 (0.003); 0.08 -0.04 (0.03); 0.11 -0.01 (0.04); 0.74 Model 3 0.16 -0.08 (0.02); <0.001 0.2 (0.6); 0.78 0.6 (0.1); <0.001 0.5 (0.6); 0.45 1.3 (0.9); 0.15 -0.03 (0.02); 0.21 -0.01 (0.04); 0.74 Age≥60 0.16 -0.11 (0.06); 0.05 1.3 (0.8); 0.10 0.8 (0.2); <0.001 0.3 (0.8); 0.75 0.3 (1.0); 0.81 -0.03 (0.03); 0.28 0.00 (0.04); 0.96 Model 4 0.14 -0.07 (0.02); <0.001 0.0 (0.7); 0.98 0.6 (0.1); <0.001 0.6 (0.7); 0.42 0.004 (0.003); 0.10 -0.04 (0.02); 0.09 -0.02 (0.04); 0.65 Age≥60 0.16 -0.07 (0.07); 0.30 1.2 (0.9); 0.19 0.8 (0.2); <0.001 0.8 (1.0); 0.39 0.005 (0.003); 0.09 -0.05 (0.03); 0.11 -0.02 (0.05); 0.72 Composite Score a Model 1 0.29 -0.02 (0.002); <0.001 0.1 (0.07); 0.15 0.08 (0.01); <0.001 0.05 (0.07); 0.49 Age≥60 0.22 -0.03 (0.007); <0.001 0.2 (0.10); 0.07 0.08 (0.02); <0.001 -0.03 (0.10); 0.76 Model 2 0.30 -0.02 (0.002); <0.001 0.1 (0.07); 0.12 0.07 (0.01); <0.001 0.08 (0.07); 0.31 5e-04 (3e-04); 0.09 -0.002 (0.003); 0.42 -0.01 (0.004); 0.02 Age≥60 0.22 -0.03 (0.007); <0.001 0.2 (0.10); 0.06 0.08 (0.02); <0.001 0.01 (0.11); 0.95 3e-04 (4e-04); 0.37 -0.002 (0.003); 0.62 -0.01 (0.006); 0.30 Model 3 0.31 -0.02 (0.002); <0.001 0.1 (0.07); 0.08 0.08 (0.01); <0.001 0.07 (0.07); 0.36 0.27 (0.10); 0.009 -0.002 (0.002); 0.52 -0.01 (0.004); 0.02 Age≥60 0.22 -0.03 (0.007); <0.001 0.2 (0.10); 0.06 0.08 (0.02); <0.001 -0.01 (0.11); 0.94 0.08 (0.13); 0.52 -0.001 (0.003); 0.74 -0.005 (0.006); 0.35 Model 4 0.26 -0.02 (0.002); <0.001 0.1 (0.08); 0.23 0.07 (0.01); <0.001 0.07 (0.08); 0.40 4e-04 (3e-04); 0.19 -0.002 (0.003); 0.40 -0.01 (0.004); 0.02 Age≥60 0.17 -0.03 (0.008); 0.001 0.2 (0.11); 0.11 0.06 (0.02); 0.003 0.00 (0.12); 0.99 2e-04 (4e-04); 0.65 -0.002 (0.004); 0.69 -0.01 (0.006); 0.29
Data are: Linear regression model adjusted R 2 ; coefficient (SE); p-value. P-values less than 0.05 are colored blue and p-values less than 0.01 are colored green. Model 1 = Age, Gender, Education, and APOE ε4 (no ε4 alleles vs. at least one ε4 allele). Model 2 = Model 1 plus baseline CSF Aβ 42 (pg/ml), total tau (pg/ml), and F 2 -IsoPs (pg/ml). Model 3 = Model 2 but uses dichotomous Aβ 42 based on <= 192 pg/ml (n=46; >=60, n=30) vs. > 192 pg/ml (n=269; >=60, n=137). Model 4 = Model 2 but excludes subjects who had any cognitive abnormality at the final diagnosis (n = 288; age >=60, n=140).
For Immediate Recall, Delayed Recall, and Animal Category Fluency, a higher score reflects better cognitive function; for Trail Making Test Parts A and B, a lower score reflects better cognitive function. a Composite Score: average of the z-score for Immediate Recall, the z-score for Delayed Recall, -1 times the z-score for Trail Making Test A, -1 times the z-score for Trail Making Test B, and the z-score for Animal Category Fluency. 0.31 0.004 (5e-04); <0.001 -0.03 (0.02); 0.05 -0.01 (0.003); <0.001 0.02 (0.02); 0.24 -1e-04 (6e-05); 0.05 5e-04 (6e-04); 0.41 0.003 (0.001); 0.007 APOE Dose 0.31 0.004 (5e-04); <0.001 -0.03 (0.02); 0.05 -0.01 (0.003); <0.001 0.007 (0.01); 0.52 -1e-04 (6e-05); 0.04 5e-04 (6e-04); 0.37 0.003 (0.001); 0.006 Category Fluency Model 1 0.16 -0.09 (0.02); <0.001 0.2 (0.6); 0.76 0.6 (0.1); <0.001 0.4 (0.6); 0.53 APOE Dose 0.16 -0.09 (0.02); <0.001 0.2 (0.6); 0.71 0.6 (0.1); <0.001 -0.1 (0.4); 0.82 Model 2 0.16 -0.08 (0.02); <0.001 0.1 (0.6); 0.85 0.6 (0.1); <0.001 0.6 (0.6); 0.35 0.004 (0.002); 0.07 -0.04 (0.02); 0.10 -0.02 (0.04); 0.63 APOE Dose 0.16 -0.08 (0.02); <0.001 0.2 (0.6); 0.80 0.6 (0.1); <0.001 0.0 (0.4); 1.00 0.004 (0.002); 0.10 -0.03 (0.02); 0.12 -0.02 (0.04); 0.65 Composite Score a Model 1 0.29 -0.02 (0.002); <0.001 0.1 (0.07); 0.15 0.08 (0.01); <0.001 0.05 (0.07); 0.49 APOE Dose 0.29 -0.02 (0.002); <0.001 0.1 (0.07); 0.16 0.08 (0.01); <0.001 0.04 (0.05); 0.41 Model 2 0.30 -0.02 (0.002); <0.001 0.1 (0.07); 0.12 0.07 (0.01); <0.001 0.08 (0.07); 0.31 5e-04 (3e-04); 0.09 -0.002 (0.003); 0.42 -0.01 (0.004); 0.02 APOE Dose 0.30 -0.02 (0.002); <0.001 0.1 (0.07); 0.12 0.07 (0.01); <0.001 0.05 (0.05); 0.30 5e-04 (3e-04); 0.09 -0.002 (0.003); 0.44 -0.01 (0.004); 0.02
Data are: Linear regression model adjusted R 2 ; coefficient (SE); p-value. P-values less than 0.05 are colored blue and p-values less than 0.01 are colored green. Model 1 = Age, Gender, Education, and APOE ε4 (no ε4 alleles vs. at least one ε4 allele). Model 2 = Model 1 plus baseline CSF Aβ 42 (pg/ml), total tau (pg/ml), and F 2 -IsoPs (pg/ml). APOE Dose Model = Same as model above it but APOE ε4 coded as: ε2/ε2 = -2, ε2/ε3 = -1, ε2/ε4 = 0, ε3/ε3 = 0, ε3/ε4 = 1, ε4/ε4 = 2. For Immediate Recall, Delayed Recall, and Animal Category Fluency, a higher score reflects better cognitive function; for Trail Making Test Parts A and B, a lower score reflects better cognitive function. a Composite Score is the average of the z-score for Immediate Recall, the z-score for Delayed Recall, -1 times the z-score for Trail Making Test A, -1 times the z-score for Trail Making Test B, and the zscore for Animal Category Fluency eFigure 1. Baseline test score versus age for 315 cognitively normal subjects.
Plotting symbols: orange open circle (o) = subjects with no clinical follow-up (n=153), black open square (□) = subjects who remained cognitively normal (n=135), magenta asterisk (*) = converted to MCI (n=14), blue solid triangle () = converted to AD (n=7), red solid circle ()= converted to other dementias or cognitive impairments (n=6). Solid line is fitted least squares line unadjusted for any covariates; green dashed lines are 95% confidence bounds for the line. A. Immediate Recall slope = -0.04, 95% CI = [-0.06, -0.02], r 2 = 0.03, p = 0.001. B. Delayed Recall slope = -0.06, 95% CI = [-0.08, -0.04], r 2 = 0.07, p < 0.001. C. log 10 Trail Making Test A slope = 0.004, 95% CI = [0.003, 0.005], r 2 = 0.24, p < 0.001. D. log 10 Trail Making Test B slope = 0.005, 95% CI = [0.004, 0.006], r 2 = 0.24, p < 0.001. E. Category Fluency slope = -0.1, 95% CI = [-0.13, -0.06], r2 = 0.09, p < 0.001. 
